The Emerging Role of the IL-17B/IL-17RB Pathway in Cancer.
| Autor: | Bastid J; OREGA Biotech, Ecully, France., Dejou C; OREGA Biotech, Ecully, France., Docquier A; OREGA Biotech, Ecully, France., Bonnefoy N; IRCM, Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Université de Montpellier, Institut Régional du Cancer de Montpellier, Montpellier, France. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Frontiers in immunology [Front Immunol] 2020 Apr 21; Vol. 11, pp. 718. Date of Electronic Publication: 2020 Apr 21 (Print Publication: 2020). |
| DOI: | 10.3389/fimmu.2020.00718 |
| Abstrakt: | Among inflammatory mediators, a growing body of evidence emphasizes the contribution of the interleukin 17 (IL-17) cytokine family in malignant diseases. Besides IL-17A, the prototypic member of the IL-17 family, several experimental findings strongly support the role of the IL-17B/IL-17 receptor B (IL-17RB) pathway in tumorigenesis and resistance to anticancer therapies. In mouse models, IL-17B signaling through IL-17RB directly promotes cancer cell survival, proliferation, and migration, and induces resistance to conventional chemotherapeutic agents. Importantly, recent work by our and other laboratories showed that IL-17B signaling dramatically alters the tumor microenvironment by promoting chemokine and cytokine secretion which foster tumor progression. Moreover, the finding that elevated IL-17B is associated with poor prognosis in patients with pancreatic, gastric, lung, and breast cancer strengthens the results obtained in pre-clinical studies and highlights its clinical relevance. Here, we review the current understanding on the IL-17B/IL-17RB expression patterns and biological activities in cancer and highlight issues that remain to be addressed to better characterize IL-17B and its receptor as potential targets for enhancing the effectiveness of the existing cancer therapies. (Copyright © 2020 Bastid, Dejou, Docquier and Bonnefoy.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|